Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Optimizing survival in advanced prostate cancer: CHAARTED: What are the implications for the future?

ESMO 2014

26 - 30 Sep 2014

Sorry, this item is currently unavailable.

Published: 29 Jan 2015

Views: 4049

Rating:

Save

Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Prof Sweeney discusses the CHAARTED trial (ChemoHormonal Therapy versus Androgen Ablation Randomised Trial for Extensive Disease in Prostate Cancer) and its implications for the treatment of prostate cancer at ESMO 2014.

From the same symposium:

Welcome and introduction

Understanding PC heterogeneity to guide treatment choices

Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival

Learnings from real life practice

Related Videos

ESMO 2024: Latest updates in mRCC

Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane...

ESMO 2024: Latest updates in mRCC ( Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane Oudard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel...

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Looking at real world evidence on PSA testing in prostate cancer

Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi

Looking at real world evidence on PSA testing in prostate cancer ( Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable...

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

Digital rectal examination is not useful as a solitary screening tool for...

Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men ( Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany )

Single intensive screening intervention using PSA and Stockholm3 in combination...

Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Single intensive screening intervention using PSA and Stockholm3 in combination might reduce prostate cancer mortality ( Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany )

More from ecancer